Hasbek Zekiye, Doğan Ömer Tamer, Sarı İsmail, Yücel Birsen, Şeker Mehmet Metin, Turgut Bülent, Berk Serdar, Siliğ Yavuz
Cumhuriyet University Faculty of Medicine, Department of Nuclear Medicine, Sivas, Turkey, Phone: +90 346 258 02 53 E-mail:
Mol Imaging Radionucl Ther. 2016 Oct 5;25(3):107-113. doi: 10.4274/mirt.97269.
Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUVmax), SUVave, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size.
Serum anti-p53 Ab level was studied in three groups. Patients who underwent 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent 18F-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN=pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers.
Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p<0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUVmax, SUVave, TLG, tumor volume and tumor size of patients with lung cancer (p>0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p>0.05).
It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion.
p53基因的突变是恶性肿瘤中最常见的基因异常。本研究的目的是评估血清抗p53抗体（Ab）的诊断价值，以及血清抗p53 Ab水平与定量正电子发射断层扫描（PET）参数之间的相关性，这些参数包括最大标准化摄取值（SUVmax）、平均SUV值（SUVave）、代谢肿瘤体积、总病灶糖酵解（TLG）和肿瘤大小。
在三组中研究血清抗p53 Ab水平。第一组为因先前诊断的肺癌分期而接受18F-氟脱氧葡萄糖（FDG）PET/计算机断层扫描（CT）成像的患者，第二组为因胸部CT检测到可疑肺结节而接受18F-FDG PET/CT成像且未显示病理性FDG摄取（非摄取性肺结节，即NAPN）的患者，第三组由健康志愿者组成。
本研究纳入了28例肺癌患者（中位年龄：62.5岁，范围：39 - 77岁）、28例非摄取性肺结节患者（中位年龄：65岁，范围：33 - 79岁）和24名健康志愿者（中位年龄：62岁，范围：44 - 74岁）。健康志愿者的血清抗p53 Ab水平较低，而肺癌患者和非摄取性肺结节患者的血清抗p53 Ab水平较高（p<0.05）。当评估血清抗p53 Ab水平和PET参数时，肺癌患者的血清抗p53 Ab水平与SUVmax、SUVave、TLG、肿瘤体积和肿瘤大小之间无显著相关性（p>0.
